Literature DB >> 8116672

Mutation analysis of 28 Gaucher disease patients: the Australasian experience.

B D Lewis1, P V Nelson, E F Robertson, C P Morris.   

Abstract

Gaucher disease is the most common lysosomal storage disease. It is an autosomal recessive disorder that results from a deficiency of beta-glucocerebrosidase. Three clinical phenotypes have been described: non-neuronopathic, acute neuronopathic, and subacute neuronopathic. Genomic DNA from 28 Australasian patients of diverse ethnic origin with Gaucher disease was screened for 3 common mutations (1226G, 1448C and 84GG) using the amplification refractory mutation system (ARMS), and one uncommon mutation (1504T) by restriction enzyme digestion. Thirty-eight of the 56 independent alleles in these patients were characterized, with 1448C present in 42% and 1226G in 28% of the alleles. The 1226G mutation was associated only with the non-neuronopathic phenotype and 7 of the 15 patients who carried the 1448C mutation developed neuronopathic disease. Three infants who died in the neonatal period following a rapidly progressive neurodegenerative course carried no identifiable mutations. The 84GG mutation was carried by 2 Jewish patients and 1504T was present in one patient. It is now possible to rapidly identify the common Gaucher mutations using ARMS and restriction enzyme digestion, and our findings confirm the heterogeneity of mutations in Gaucher disease. It is also possible to predict in part the phenotypic outcome when screening patients for these mutations. We consider mutation analysis to be of most use in prenatal diagnosis and for carrier detection within affected families.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8116672     DOI: 10.1002/ajmg.1320490212

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  5 in total

1.  The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease.

Authors:  E Sidransky; N Tayebi; B K Stubblefield; W Eliason; A Klineburgess; G P Pizzolato; J N Cox; J Porta; A Bottani; C D DeLozier-Blanchet
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

Review 2.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

3.  Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations.

Authors:  H Ida; K Iwasawa; H Kawame; O M Rennert; K Maekawa; Y Eto
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

4.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 5.  Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana Matos; Sandra Alves
Journal:  Diseases       Date:  2016-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.